Displaying drugs 2676 - 2700 of 3188 in total
Pegozafermin
Pegozafermin is under investigation in clinical trial NCT05852431 (To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia).
Investigational
AZD-6280
AZD6280 has been used in trials studying the basic science of Anxiety.
Investigational
Matched Iupac: … 4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide …
Olokizumab
Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome....
Investigational
Tuparstobart
Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS ≥ 1) Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck).
Investigational
Odanacatib
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.
Investigational
5beta-dihydrotestosterone
Experimental
10-formyl-5,8,10-trideazafolic acid
Experimental
6,8-DIMERCAPTO-OCTANOIC ACID AMIDE
Experimental
BC9KBY85WY
Investigational
INHIBITOR Q8467 OF DUPONT MERCK
Experimental
N-Methylmesoporphyrin containing copper
Experimental
KIN-3248
KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. While effective, disease progression may occur 6 to 8 months...
Investigational
Matched Description: … [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently …
BNT162b1 SARS-CoV-2 Vaccine
BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived from T4 fibritin...
Investigational
Matched Description: … a phase 1/2 study in 45 healthy adult volunteers demonstrated RBD-binding immunoglobulin levels and 50% …
Diphenyleneiodonium
An NADPH oxidase 2 (NOX2) inhibitor.
Investigational
Matched Iupac: … 8lambda3-iodatricyclo[7.4.0.0^{2,7}]trideca-1(9),2,4,6,10,12-hexaen-8-ylium …
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a is under investigation in clinical trial NCT01668823 (Photodynamic Therapy in Treating Patients With Lung Cancer).
Investigational
Calystegine B2
Experimental
Matched Iupac: … (1R,2S,3R,4S,5R)-8-azabicyclo[3.2.1]octane-1,2,3,4-tetrol …
Fenspiride
Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as...
Experimental
Matched Iupac: … 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one …
Mibefradil
Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Investigational
Withdrawn
Matched Salts cas: … 116666-63-8 …
Cinitapride
Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.
Investigational
Velusetrag
Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance. Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research...
Investigational
Matched Iupac: … N-[(1R,3R,5S)-8-[(2R)-2-hydroxy-3-(N-methylmethanesulfonamido)propyl]-8-azabicyclo[3.2.1]octan-3-yl]- …
BMS-986142
BMS-986142 is under investigation in clinical trial NCT02880670 (Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects).
Investigational
Matched Iupac: … (2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide ... (2S)-6-fluoro-5-[3-(8-fluoro-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)-2-methylphenyl]-2- …
LM-030
Investigational
Displaying drugs 2676 - 2700 of 3188 in total